SEMAWIN 0.25mg Injection

AboutSEMAWIN 0.25mg Injection contains Semaglutide 0.25mg starting dose, a GLP-1 receptor agonist for initiating diabetes and weight management therapy.Usage Instructions: Inject subcutaneously once weekly. Rotate injection sites. Use as starting dose for 4 weeks before escalating to higher doses. Follow pen instructions.Benefits: Initiates blood sugar control, begins weight reduction process, establishes treatment tolerance, once-weekly convenience.How it Works: Activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, reducing appetite.Side Effects: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, reduced appetite, injection site reactions.Safety Advice: Contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2. Monitor for pancreatitis. Use caution in renal impairment. Discontinue if severe hypersensitivity occurs.Storage: Refrigerate at 2-8°C before first use. After initiation, may store at room temperature (up to 30°C) for up to 6 weeks. Do not freeze. Protect from light.